Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Capital Markets Day

On June 15th, Oasmia Pharmaceutical AB held a Capital Markets Day in Stockholm.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.


At Oasmia, we’re developing the next generation of drugs with focus on oncology.


At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share


Issuance of warrants in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (the ”Company”) resolved, at the Extraordinary General Meeting of the Company on 2 June 2017, to establish two warrant programmes, series 2017:1 and series 2017:2, ...
Read more

Oasmia Pharmaceutical AB (publ) publishes prospectus by reason of the Rights Issue

The board of directors of Oasmia Pharmaceutical AB (publ) (”Oasmia”, ”Company” or “Group”) has prepared a prospectus (“Prospectus”) concerning the new issue of shares with preferential...
Read more

Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets

Oasmia replaces previous distribution agreement with Hetero Group, a global group of Companies, representing a large operation with expanding capabilities
Read more
To news archive